[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scleroderma-limited-and-diffuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scleroderma-limited-and-diffuse":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,78,95,111,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100615465","investigating-the-effectiveness-of-the-biopsychosocial-model-based-exercise-approach-in-children-and-adults-diagnosed-with-scleroderma-100615465",false,"NCT07292961","Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma","Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach (BETY) in Children and Adults Diagnosed With Scleroderma: A Single-Blind Randomized Controlled Trial","\\*For a child diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* History of developmental delay\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\n\\*For adults diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study","ALL","7 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to investigate the effectiveness of BETY, an exercise approach based on the biopsychosocial model, in children and adults diagnosed with scleroderma.",[26,27,28,29,30,31,32],"Scleroderma","Scleroderma, Localized","Scleroderma Systemic","Scleroderma (Limited and Diffuse)","Systemic Sclerosis (SSc)","Systemic Sclerosis - 2013 ACR\u002FEULAR Classification Criteria","Juvenile Systemic Sclerosis",[34,35,36,37],"biopsychosocial model","exercise","scleroderma","juvenile scleroderma","RECRUITING","2025-12-06",{"date":41,"type":42},"2025-12-18","ACTUAL",{"date":44,"type":42},"2025-12-04",{"date":46,"type":20},"2027-12-04",{"name":48,"class":49},"Hacettepe University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100607016","patients-diagnosed-with-scleroderma-physical-performance-and-functionality-100607016","NCT07183072","Patients Diagnosed With Scleroderma: Physical Performance and Functionality","Investigating the Relationship Between the Biopsychosocial Status of Individuals Diagnosed With Scleroderma and Their Physical Performance and Functionality","\\*For a child diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\n\\*For adults diagnosed with scleroderma\\*\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study",{"count":59,"type":20},50,"2 Weeks","OBSERVATIONAL","Physical functionality and performance are important for individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. In light of all this literature, the aim was to evaluate the biopsychosocial characteristics of both pediatric and adult scleroderma patients and to examine their physical performance and functionality.\n\nAdditionally, this study aims to identify effective tests that can be used in future research to assess physical performance and functionality in individuals diagnosed with scleroderma.",[30,26,29,27,64],"Functionality",[66,36,67,68,69],"Juvenile scleroderma","systemic sclerosis","physical performance","functionality","2025-09-13",{"date":72,"type":42},"2025-09-19",{"date":74,"type":42},"2025-08-04",{"date":76,"type":20},"2027-08-04",{"name":48,"class":49},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":94,"locationsCount":50},"100607008","cultural-adaptation-validity-and-reliability-of-the-turkish-version-of-the-pastul-questionnaire-100607008","NCT07182968","Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire","Cultural Adaptation, Validity, and Reliability of the Turkish Version of the Patient Assessment of Skin Thickness in the Upper Limb - PASTUL Questionnaire","Inclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals aged 18 years and older\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are unwilling to participate","18 Years",{"count":59,"type":20},"The Patient Self-Assessment of Skin Thickness in Upper Limb (PASTUL) questionnaire was developed to enable patients to assess skin thickness in systemic sclerosis (SSc) physically and has been validated for reliability and validity, as it correlates with the modified Rodnan Skin Score (mRSS), which rheumatologists assess. Thus, it has been demonstrated to be an applicable and easy approach for assessing skin thickness in SSc patients through patient-reported measurements. This study aimed to develop a Turkish version of the PASTUL questionnaire and to provide for its use in the Turkish population.",[30,89,29,90],"Systemic Sclerosis (Scleroderma)","Patient Perspective",{"date":72,"type":42},{"date":74,"type":42},{"date":76,"type":20},{"name":48,"class":49},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":110,"locationsCount":50},"100607009","patients-diagnosed-with-scleroderma-and-their-chewing-and-swallowing-performance-100607009","NCT07182981","Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance","Investigating the Relationship Between the Biopsychosocial Status of Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance","For a child diagnosed with scleroderma:\n\nInclusion Criteria:\n\n* Cases diagnosed with scleroderma,\n* Cases aged 7-18 years will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Cases that are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study\n\nFor adults diagnosed with scleroderma:\n\nInclusion Criteria:\n\n* Individuals diagnosed with scleroderma,\n* Individuals over the age of 18 will be included.\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, and malignancies\n* Individuals who are not willing to participate in the study will be excluded.\n* Having participated in a regular exercise program for the past 3 months\n* Individuals who are not willing to participate in the study",{"count":59,"type":20},"It is recommended to focus on the physical functionality, chewing, and swallowing performance of individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. The aim was to assess the biopsychosocial characteristics of both children and adults diagnosed with scleroderma and to examine their chewing and swallowing performance.\n\nAdditionally, this study aims to identify effective scales that can be used in future research to assess chewing and swallowing in individuals diagnosed with scleroderma.",[30,26,29,27,105],"Swallowing",[66,36,67],{"date":72,"type":42},{"date":74,"type":42},{"date":76,"type":20},{"name":48,"class":49},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":16,"minAge":85,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100594101","pathogenic-mechanisms-involved-in-the-initiation-and-progression-of-systemic-sclerosis-100594101","NCT07015060","Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis","Inclusion Criteria:\n\n* Patients diagnosed with one of the following:\n\n  * Limited SSc\n  * Limited cutaneous SSc\n  * Diffuse cutaneous SSc\n* Patients followed regularly in consultations at CUSL.\n* Patients between ages 18-80.\n\nExclusion Criteria:\n\n* Other (co-occurring) autoimmune\u002Fautoinflammatory disease\n* Pregnancy\n* Participants with temporary or definitive disabilities to give consent\n* Participants unable to sign or read the inform consent form",true,"80 Years",{"count":120,"type":20},15,[23],"Identify rare variants in candidate genes and pathways identified in familial SSc, in patients with sporadic SSc.\n\nPerform (spatial) transcriptomic and proteomic analyses of affected skin from patients with and without cutaneous fibrosis, for the patterns and levels of expression\u002Factivation of candidate genes and pathways.\n\nTest for dysregulation of expression\u002Factivation of candidate genes and pathways in live cells isolated from the blood and skin biopsy of patients, and for the impact of these dysregulations on cell appearance, behavior and function.",[29],"NOT_YET_RECRUITING","2025-06-02",{"date":127,"type":42},"2025-06-11",{"date":129,"type":20},"2025-06",{"date":131,"type":20},"2031-03",{"name":133,"class":49},"Université Catholique de Louvain",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100568661","respiratory-muscle-training-in-scleroderma-100568661","NCT06684132","Respiratory Muscle Training in Scleroderma","Effects of Respiratory Muscle Training in Patients With Scleroderma With Pulmonary Involvement","Inclusion Criteria:\n\n* 18-65 years old\n* Patients whose medical treatment has not changed in the last three months\n* Patients who volunteered to participate in the study and were cooperative\n* Literate patients\n* Patients followed with a diagnosis of SSc\n\nExclusion Criteria:\n\n* Patients who are pregnant\n* Patients with a diagnosis of malignancy\n* Patients with other concomitant systemic inflammatory rheumatic diseases\n* Patients with neurological, orthopedic or congenital problems that prevent physical activity","65 Years",{"count":143,"type":20},30,[23],"The aim of this study is to investigate the effects of IMT on respiratory muscle strength, pulmonary function tests, quality of life aerobic capacity, dyspnea, fatigue and physical activity level in scleroderma patients with ILD. The study will include 30 Scleroderma + ILD patients who are under follow-up in Fırat University Rheumatology Department. Patients will be randomly divided into two groups. High intensity intermittent inspiratory muscle training (H-IMT) will be applied to the respiratory muscle training group in addition to the exercise program. Respiratory muscle strength will be assessed by maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP); aerobic capacity will be assessed by exercise test and VO2max. Dyspnea will be assessed with the Modified Medical Research Council Scale; fatigue with the Fatigue Severity Scale; quality of life with the Scleroderma Health Assessment Questionnaire; physical activity level with the International Physical Activity Scale - Short Form",[29],[26,148,149],"Inspiratory muscle training","pulmonary functions","2024-11-11",{"date":152,"type":42},"2024-11-12",{"date":154,"type":20},"2024-11-10",{"date":156,"type":20},"2025-02-20",{"name":158,"class":49},"Firat University"]